BSR Intelligence
Daily intelligence on the peptide research industry.
Independent briefings on regulatory moves, pharma deals, research pipeline shifts and the trust gaps that define this market. Updated daily, sourced inline.
The week's Intelligence in one email, every Friday morning.
Regulatory moves, trial readouts, supply-chain news. No product pitches. Unsubscribe in one click.
Regulatory & Policy · 21 Aug 2026
FDA's Proposed 503B Exclusion of Compounded GLP-1s: What the NPRM Means, Where the Rule Stands, and What Research Suppliers Need to Know
The FDA's April 2026 notice of proposed rulemaking would permanently bar 503B outsourcing facilities from bulk-compounding semaglutide, tirzepatide, and liraglutide. The public comment period has closed and a final rule is pending — a development that stands in sharp contrast to the July PCAC votes favouring expanded access to non-GLP-1 peptides.
Read briefing →
Research Pipeline
BPC-157 After the PCAC Vote: What the 8-6 Decision Means, Where the Evidence Stands, and What Comes Next
The FDA's Pharmacy Compounding Advisory Committee voted 8-6 on 23 July 2026 to recommend BPC-157 for the 503A Bulk Drug Substances List — overruling its own career scientists. The vote is non-binding, formal rulemaking will take at least 12 months, and the human evidence base remains extremely thin. This briefing sets out what the decision means in practice for research procurement teams.
20 Aug 2026
Research Pipeline
Semax: The ACTH-Derived Neuropeptide With a Favourable PCAC Vote, Three Decades of Russian Clinical Use, and No Western Regulatory Approval
Semax, a synthetic heptapeptide derived from adrenocorticotropic hormone, received a favourable PCAC recommendation on 24 July 2026 for inclusion on the FDA's 503A compounding list. This briefing examines its mechanism, the evidence base from Russian clinical programmes, and its current regulatory standing in the US, UK, and EU — a picture of a compound with an unusually long clinical history but no recognised approval outside Russia and certain CIS states.
19 Aug 2026
Research Pipeline
Retatrutide: Four Phase 3 Trials Complete, BLA Filing Set for Q1 2027 — What the TRIUMPH Data Mean for the Peptide Research Landscape
Eli Lilly completed its four-trial TRIUMPH Phase 3 programme on 23 July 2026 with positive readouts from TRIUMPH-2 and TRIUMPH-3, recording up to 22.6% weight loss in high-risk cardiovascular populations. A Biologics Licence Application is now planned for Q1 2027, making retatrutide the first triple hormone receptor agonist to advance to regulatory submission.
18 Aug 2026
Research Pipeline
KPV: The Anti-Inflammatory Tripeptide With a PCAC Vote, a Compelling Preclinical Mechanism, and No Confirmed Human Trials
KPV — the three-amino-acid C-terminal fragment of alpha-melanocyte-stimulating hormone — received a narrow 8-6 PCAC recommendation for inclusion on the FDA's 503A Bulk Drug Substances List in July 2026. Its NF-κB inhibitory mechanism is well-characterised in cell and animal models, but no controlled human trials have confirmed clinical benefit, leaving procurement teams in a familiar position: strong mechanistic rationale, thin translational evidence, and an unresolved regulatory pathway.
17 Aug 2026
Research Pipeline
MOTS-c: The Mitochondrial-Encoded Peptide With a PCAC Vote, an Active Human Trial, and an Unresolved Regulatory Path
MOTS-c is a 16-amino-acid peptide encoded within mitochondrial DNA that has drawn sustained research interest for its role in metabolic regulation and exercise adaptation. Following the July 2026 PCAC vote recommending it for the FDA 503A Bulks List, procurement teams should understand where the evidence base stands and what remains unresolved before any lawful compounding pathway exists.
16 Aug 2026
Regulatory & Policy
Louisiana's Act 374: The First US State Law Shielding Peptide Prescribers — What It Means for the Regulatory Landscape
Louisiana's Senate Bill 253, now Act 374, came into force on 1 August 2026, becoming the first enacted US state statute to bar professional licensing boards from preventing qualified prescribers from offering patients peptides sourced from compliant 503A or 503B facilities. The law is a tangible downstream consequence of the MAHA-influenced federal reclassification drive and illustrates the patchwork state-level dynamic that shapes peptide supply chains reaching UK research institutions.
15 Aug 2026
Research Pipeline
TB-500 and Thymosin Beta-4: Mechanism, Evidence Base, and Regulatory Position After the July 2026 PCAC Vote
TB-500 is the synthetic research peptide most associated with thymosin beta-4, a naturally occurring actin-sequestering protein with preclinical evidence across wound healing, cardiac repair, and neural tissue models. A June 2026 scoping review mapped 80 published studies, and the FDA's PCAC voted in July 2026 to recommend the compound for the 503A compounding list — a non-binding step that leaves its formal regulatory status unchanged for now.
14 Aug 2026
Research Pipeline
Epitalon: Mechanism, Evidence Base, and Regulatory Position After the July 2026 PCAC Vote
Epitalon is a synthetic tetrapeptide developed over four decades of Russian research and centred on proposed telomerase activation and pineal-gland regulation. Following the PCAC's 7-to-4 vote in its favour on 24 July 2026, it now sits closer to legitimate US compounding than at any previous point — though formal 503A listing remains months of rulemaking away. This profile examines what the evidence actually shows and what the regulatory path forward means for UK research procurement.
13 Aug 2026
Research Pipeline
Thymosin Alpha-1: The 28-Amino-Acid Immunomodulator With Decades of Clinical Data — Mechanism, Evidence, and Regulatory Position in 2026
Thymosin alpha-1 (Tα1) carries one of the deepest clinical records of any peptide in active research — more than 11,000 human subjects, approval in roughly 35 countries, and a long-running debate over its status in the United States and United Kingdom. This briefing examines its mechanism, what the evidence base actually supports as of 2026, and where the compound sits within the ongoing US reclassification process.
12 Aug 2026
Industry & Community
Samsung Biologics' $1.8 Billion PolyPeptide Acquisition: What Peptide CDMO Consolidation Means for Research Supply Chains
Samsung Biologics has launched an all-cash tender offer to acquire Swiss peptide CDMO PolyPeptide Group for approximately $1.8 billion — the largest biopharma acquisition in South Korean history. With the formal offer prospectus due by 31 August 2026, procurement teams should understand what accelerating CDMO consolidation means for peptide API availability and supply-chain resilience.
11 Aug 2026
Regulatory & Policy
FDA's 503B GLP-1 Exclusion Proposal: Comment Period Closed, Final Determination Pending — What Research Procurement Teams Should Know
The FDA's proposal to permanently exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulks List has passed its public comment deadline. With the agency now reviewing submissions before issuing a final determination, research-procurement professionals face a narrowing window for sourcing compounded GLP-1 reference material through regulated large-scale channels.
10 Aug 2026